Alzheimer's Disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major component of these plaques is Ab peptide (b-amyloid), a 40 to 43aa peptide cleaved from amyloid precursor protein (APP). Increased release of the 'longer forms' of Ab peptide, Ab42 or Ab43, which have a greater tendency to aggregate than Ab40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alleles, or may involve other, still undiscovered, factors. Many researchers theorize that this increased release of Ab42/Ab43 leads to the abnormal deposition of Ab and the associated neurotoxicity in the brains of affected individuals.
Applications:
Suitable for use in ELISA, Western Blot, and Immunocytochemistry. Other applications not tested.
Recommended Dilution:
ELISA: 0.05ug/ml
Western Blot: 1ug/ml
Immunocytochemistry: 0.1-1ug/ml
Optimal dilutions to be determined by the researcher.
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Reconstitute with sterile 40-50% glycerol, aliquot and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Quick Search
Products 
